Jeff Aronin, chairman and also the Executive Chief Officer of Paragon Biosciences organization. He is an investor and incubator and the companies help the people struggling with diseases where there are little treatment available options or don’t exist at all.
For the last 10 years, Drug and Food Administration has approved new medications which are under Paragon Biosciences leadership. The company has been able to accomplish this following three strategies; building, identification, and future developments of products.
Jeff and his colleagues from the company find it very important being to be able to develop disease treatments which have little or lack treatment option. What they try to do first is to be able to identify the need for paragon work. The company does considerations for population size affected and availability of any treatments that doctors are offering the patients.
Paragon then will later investigate the patients and their conditions thoroughly so that they can examine the science behind the disease so that they can be able to address what people needs best. When driving its drug development strategy, the company checks the clinical studies together with the scientific data.
After they have successfully identified the disease, they will address a new drug. Paragon Biosciences will create dynamic companies which help to create the medicine. It may even take even several years so that they can get life-changing medicine for the patients. Paragon will provide long-term resources and also all necessary support to the portfolio companies so that they can ensure that the drug developer has been processed efficiently.
Paragon companies have advanced rapidly with the medicine especially to those lacking treatment options. This is after they apply for breakthrough science which focuses on high-unmet medical areas in need. In many different cases, drugs that are created by Paragon’s companies become the first and approved treatments for the target disease.
The drugs which have been created by Paragon Biosciences have become instrumental to change the lives of many patients. An example of the company is Castle Creek which has lately been focusing on the development of innovative therapies for serious, rare or having debilitating dermatologic conditions patients. It has several products which are for the late development stages.